Basic information Synthesis Safety Related Supplier

ChemicalBook Product Catalog API Fluid, Electrolyte, and Acid-Base Balance Electrolyte Balance Pharmacology Etidronic acid

1/1

Etidronic acid NEW

$ 31.00 /500mg

Min. Order
Purity≥95%
Cas No2809-21-4
Supply Ability10g
Update time2024-11-19

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

1YR

United States

show more

Chemical Properties

Product Name	Etidronic acid
CAS No	2809-21-4
EC-No
Min. Order
Purity	≥95%
Supply Ability	10g
Release date	2024/11/19

Product Introduction

Bioactivity

Name	Etidronic acid
Description	Etidronic acid (HEDP) is a diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
In vitro	Etidronate inhibits directly osteoclastic bone-resorbing activity by pit assay. Etidronate also directly induces apoptosis and disrupts actin rings in osteoclasts. [1]
In vivo	Etidronate, when administered s.c. repeatedly at 10 or 40 mg/kg/day, gradually suppresses the adjuvant-induced allodynia In the rats with adjuvant arthritis, as assessed by 10-g von Frey hair. Etidronate (10-40 mg/kg/day) suppresses the adjuvant-induced mechanical allodynia in rat hindpaw. Etidronate (5–10 mg/kg/day) dose-dependently prevents the decrease in bone mineral density (BMD) in the proximal tibia of the arthritic rats. [2] Etidronate inhibits the histidine decarboxylase induction, but not the other inflammatory reactions induced by alendronate. Etidronate (unlike clodronate) also inhibits alendronate-induced BP-line formation in mice (even at 40 mmol/kg). Etidronate (160 mmol/kg) also inhibits the physicochemical changes in the tibia induced by six, weekly injections of alendronate. [3] Etidronate (10 mg/kg) combined with Calcitriol after subtotal nephrectomy (SNx) significantly inhibits thoracic and abdominal aortic calcification 3 weeks after the operation in rats. [4] Etidronate (5 mg/kg or 10 mg/kg) significantly reduces the thoracic and abdominal aortic calcification induced by calcitriol in the renal failure rat. Etidronate (5 mg/kg or 10 mg/kg) also reduces the dysfunction in aortic contraction. Etidronate (5 mg/kg) reverses the reduction in the aortic expression of matrix Gla protein mRNA observed in nephrectomized rats. [5]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 45 mg/mL (218.41 mM)
Keywords	Paget's disease \| osteoporosis \| MCF-7 \| Inhibitor \| inhibit \| Etidronic acid \| arterial calcification \| Apoptosis
Inhibitors Related	Stavudine \| 5-Fluorouracil \| Acetylcysteine \| Myricetin \| Dextran sulfate sodium salt (MW 4500-5500) \| Sodium 4-phenylbutyrate \| L-Ascorbic acid \| Metronidazole \| Tributyrin \| Stearic acid \| Salicylic acid \| Oleic acid
Related Compound Libraries	Pain-Related Compound Library \| Bioactive Compound Library \| Drug Repurposing Compound Library \| Anti-Viral Compound Library \| Inhibitor Library \| FDA-Approved Drug Library \| Anti-Cancer Approved Drug Library \| Immunology/Inflammation Compound Library \| Cosmetic Ingredient Compound Library \| Bioactive Compounds Library Max \| Anti-Cancer Active Compound Library \| Anti-Cancer Drug Library

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book